Drugs / FXS6837
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07502638 | Mar 2026 → Sep 2027 expected | IgA glomerulonephritis | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FXS6837 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07502638 ↗ |
| Route | Oral | “FXS6837 taken orally once a day” NCT07502638 ↗ |